INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC - BRAINSTORM CELL THERAPEUTICS ownership

BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 38 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC ownership history of BRAINSTORM CELL THERAPEUTICS
ValueSharesWeighting
Q2 2024$2,031
-40.1%
6,0000.0%0.00%
-100.0%
Q1 2024$3,388
+106.8%
6,0000.0%0.00%
Q4 2023$1,638
+36.4%
6,0000.0%0.00%
Q3 2023$1,201
-80.6%
6,000
+100.0%
0.00%
-100.0%
Q2 2023$6,180
-37.6%
3,0000.0%0.00%
-50.0%
Q1 2023$9,900
+101.2%
3,0000.0%0.00%
+100.0%
Q4 2022$4,920
-62.2%
3,0000.0%0.00%
-50.0%
Q3 2022$13,000
+62.5%
3,0000.0%0.00%
+100.0%
Q2 2022$8,000
-20.0%
3,0000.0%0.00%
-50.0%
Q1 2022$10,000
-16.7%
3,0000.0%0.00%0.0%
Q4 2021$12,000
+20.0%
3,0000.0%0.00%0.0%
Q3 2021$10,000
-9.1%
3,0000.0%0.00%0.0%
Q2 2021$11,000
+37.5%
3,000
+50.0%
0.00%0.0%
Q1 2021$8,000
-11.1%
2,0000.0%0.00%0.0%
Q4 2020$9,000
-73.5%
2,0000.0%0.00%
-75.0%
Q3 2020$34,000
+54.5%
2,0000.0%0.01%
+60.0%
Q2 2020$22,000
+144.4%
2,0000.0%0.01%
+150.0%
Q1 2020$9,0000.0%2,0000.0%0.00%0.0%
Q4 2019$9,000
+12.5%
2,0000.0%0.00%0.0%
Q3 2019$8,0000.0%2,0000.0%0.00%0.0%
Q2 2019$8,000
-11.1%
2,0000.0%0.00%0.0%
Q1 2019$9,000
+28.6%
2,0000.0%0.00%0.0%
Q4 2018$7,000
-12.5%
2,0000.0%0.00%0.0%
Q3 2018$8,0000.0%2,0000.0%0.00%0.0%
Q2 2018$8,000
+33.3%
2,0000.0%0.00%
+100.0%
Q1 2018$6,0002,0000.00%
Other shareholders
BRAINSTORM CELL THERAPEUTICS shareholders Q2 2019
NameSharesValueWeighting ↓
Perceptive Advisors 400,000$1,068,0000.09%
SABBY MANAGEMENT, LLC 493,191$1,317,0000.07%
GUARDIAN CAPITAL ADVISORS LP 10,000$23,0000.00%
A.R.T. Advisors, LLC 22,758$60,0000.00%
Psagot Value Holdings Ltd. 22,715$61,0000.00%
TCI Wealth Advisors, Inc. 1,100$3,0000.00%
Penserra Capital Management LLC 4,980$13,0000.00%
D'Orazio & Associates, Inc. 500$1,0000.00%
CITIGROUP INC 380$1,0000.00%
GEODE CAPITAL MANAGEMENT, LLC 61,269$163,0000.00%
View complete list of BRAINSTORM CELL THERAPEUTICS shareholders